Tripura Signs MoU with NSE To Boost Financial Literacy And Skill Development: Chief Minister Of Tripura Dr. Manik Saha.
NiveshIQ
NSE: STAR · Pharma
Strides Pharma Science Ltd.
₹1,060.00▲ ₹18.30 (+1.76%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on STAR. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Strides Pharma Science Ltd.
Strides Pharma Science Limited (STAR) is a leading Indian pharmaceutical company that develops, manufactures, and sells pharmaceutical products across various geographies. The company's core business is driven by its pharma generics offerings in various forms, including tablets, capsules, sachets, and liquids. Additionally, it develops branded generics products for chronic therapies under its own brands, such as Renerve and Unibrol. Strides Pharma Science Limited has a strong presence in Africa, Australia, North America, Europe, Asia, and internationally. The company has a diverse portfolio of products, including anti-retroviral, anti-malarial, and anti-tuberculosis drugs. With a revenue of ₹4726 Cr and net income of ₹511 Cr, the company has a strong financial foundation. As an emerging pl
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹3,979 Cr +115.00% | ₹4,565 Cr +14.70% | ₹4,859 Cr +6.40% |
| EBITDA Margin | 13.65% | 17.78% | 22.15% |
| Net Profit | -2.10% | ₹3,622 Cr -3953.10% | ₹600.89 Cr -83.40% |
| EPS | ₹-7.95 | ₹390.95 | ₹60.34 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Star Paper Mills Ltd. Revenue Breakdown – NSE:STARPAPER
Blue Star Limited Revenue Breakdown – NSE:BLUESTARCO
🔒
+ 3 more stories about Strides Pharma Science Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q4FY26 results: revenue ₹1, 323 Cr, PAT ₹129 Cr, EPS ₹13.77, EBITDA margin 18.7%. Growth context: revenue YoY +11.1%, PAT YoY +17.4%, revenue QoQ +10.7%, PAT QoQ -38.0%. Street verdict: beat, revenue surprise +0.6%, PAT surprise +15.3%.
Product pipeline delivery, domestic demand, export mix, approvals, and margin discipline remain the key forward drivers ...
FY26 (last completed FY): revenue ₹4, 859 Cr, PAT ₹601 Cr, EBITDA margin 22.1%, EPS ₹60.34. Year-on-year: revenue YoY +6...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for STAR
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track STAR alongside your other holdings
Unlock full STAR research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Strides Pharma Science Ltd.?
NiveshIQ detects active intelligence signals for Strides Pharma Science Ltd. (STAR) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Strides Pharma Science Ltd.?
Strides Pharma Science Ltd. operates in the Pharma sector with a market capitalisation of ₹1,077,499.0L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.